Simone Dokter
- Algorithms
- Billing code
- Biomarker
- Cancer of Unknown Primary
- cfDNA
- DNA
- Education
- End of Treatment
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Innovation
- IT
- Lab process
- Learning healthcare system
- Molecular diagnostics
- OncoAct
- oncoanalyser
- Participating hospitals
- Patients' stories
- Personalized treatment
- Quality
- Rare cancers
- Re-use data
- Research
- Scientific publications
- Treatment
- Uncategorized
- Whole genome sequencing
- Working in the cloud
Simone Dokter
The complete DNA test is an additional tool to help us discover the origin of the cancer in patients with …
Job van Riet
Hartwig’s unique data set has enriched our understanding of metastatic cancer.
Emile Voest
Just one WGS test is enough to reveal everything you need to know to provide a patient with metastatic cancer …
Gerrit Meijer
Cancer is caused by DNA mutations. There are an increasing number of drugs available that act on specific errors in …
Andrea van Puffelen
The knowledge we gather with WGS can bring us a step closer to our goal to find an effective and …
Warnyta Minnaard
If the practitioner doesn’t know where the primary tumor is located, they cannot offer a targeted treatment plan, and nor …
Laurens Beerepoot
In our profession, we need to know everything about the patient, but we also want to know as much as …
Miriam Koopman
A complete genetic analysis should be part of the standard diagnostics for every patient with cancer who is eligible for …
Louisa Hoes
Cancers will increasingly meet the definition of ‘rare’ in terms of the molecular profiles that make each tumor unique. The …
Ernst Kuipers
It is essential to record and share data to ensure good care.
Núria López-Bigas
The number of WGS samples Hartwig Medical Foundation has is quite unique in the research field and is rapidly growing. …
Melinda Pruis
Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing.
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.